Antiplatelet patterns and outcomes in patients with atrial fibrillation not prescribed an anticoagulant after stroke

Kay-Won Chang,Ying Xian,Xin Zhao,Xiaojuan Mi,Roland Matsouaka,Shreyansh Shah,Lee H. Schwamm,Barbara L. Lytle,Eric E. Smith,Deepak L. Bhatt,Gregg C. Fonarow,Jonathan C. Hsu

DOI: https://doi.org/10.1016/j.ijcard.2020.08.011

IF: 4.039

2020-12-01

International Journal of Cardiology

Abstract:<h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Background</h3><p>To determine association of discharge antiplatelet therapy prescription with 1-year outcomes among patients with AF admitted with acute ischemic stroke and discharged without oral anticoagulation.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Methods</h3><p>In a retrospective cohort study from the Get With The Guidelines-Stroke registry, we identified all Medicare fee-for-service beneficiaries 65 years or older with AF or atrial flutter admitted with acute ischemic stroke and discharged without oral anticoagulation from April 2003 through December 2014, and we determined association of discharge antiplatelet therapy prescription with 1-year outcomes using Medicare claims data. Primary outcomes were 1-year mortality and composite endpoint of major adverse cardiovascular/neurologic/bleeding events (MACNBE).</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Results</h3><p>Of 64,228 subjects (median [interquartile range] age, 84 [78–89] years; 62.5% female), 54,621 (85.0%) were discharged with antiplatelet therapy, and 9607 (15.0%) were discharged with no antithrombotic therapy. The unadjusted rates of 1-year mortality were lower among patients receiving antiplatelet therapy (37.3%) than among those receiving no antithrombotic therapy (48.1%); unadjusted rates of MACNBE were lower for those receiving antiplatelet therapy (45.5%) compared with those receiving no antithrombotic therapy (55.2%). After adjusting for potential confounders, antiplatelet therapy prescription was associated with reduced 1-year mortality (adjusted hazard ratio [HR] 0.64, 95% confidence interval [CI] 0.62–0.66, <em>P</em> &lt; .001) and MACNBE (adjusted HR 0.69, 95% CI 0.67–0.71, <em>P</em> &lt; .001).</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Conclusions</h3><p>Among Medicare beneficiaries with AF admitted for acute ischemic stroke but not discharged on oral anticoagulant therapy, antiplatelet therapy, compared with no antithrombotic therapy, was associated with reduced 1-year mortality and MACNBE.</p>

cardiac & cardiovascular systems

What problem does this paper attempt to address?

The problem that this paper attempts to solve is the association between anti - platelet therapy at discharge and clinical outcomes within 1 year in patients with atrial fibrillation (AF) who are hospitalized for acute ischemic stroke without being prescribed anticoagulant drugs. Specifically, the researchers want to understand:

1. **The impact of anti - platelet therapy on 1 - year mortality**: The study aims to evaluate whether there are significant differences in 1 - year mortality between patients who receive anti - platelet therapy at discharge and those who do not receive any antithrombotic therapy.
2. **The impact of anti - platelet therapy on major adverse cardiovascular/neurological/bleeding events (MACNBE)**: The study also explores whether anti - platelet therapy can reduce the risk of major adverse cardiovascular/neurological/bleeding events within 1 year.
3. **Other clinical outcomes**: The study also analyzes some other secondary outcome indicators, such as readmission for various reasons, readmission for ischemic stroke, readmission for hemorrhagic stroke, readmission for cardiovascular reasons, readmission for myocardial infarction, readmission for gastrointestinal bleeding, etc.

### Research background
Atrial fibrillation (AF) is an independent risk factor for the severity, recurrence, and death of ischemic stroke. Although oral anticoagulants (OAC) can significantly reduce the risk of ischemic stroke in AF patients, many patients fail to use OAC due to bleeding risks or other reasons. Therefore, the effectiveness of anti - platelet therapy for these patients has become the focus of research.

### Research methods
- **Data sources**: The study used the American Heart Association/American Stroke Association "Get With The Guidelines - Stroke" (GWTG - Stroke) registry data.
- **Study population**: Medicare fee - for - service beneficiaries aged 65 and older who were hospitalized for acute ischemic stroke and not prescribed OAC between April 2003 and December 2014 were included.
- **Grouping**: According to the antithrombotic therapy strategy at discharge, they were divided into two groups: the non - antithrombotic therapy group and the anti - platelet therapy group.
- **Outcome indicators**: The primary outcome indicators include 1 - year mortality and MACNBE (major adverse cardiovascular/neurological/bleeding events). Secondary outcome indicators include readmission for various reasons, readmission for ischemic stroke, readmission for hemorrhagic stroke, etc.

### Research results
- **Baseline characteristics**: Among 64,228 patients, 85.0% of the patients received anti - platelet therapy at discharge, and 15.0% of the patients did not receive any antithrombotic therapy.
- **Unadjusted results**: Patients who received anti - platelet therapy had lower 1 - year mortality (37.3% vs 48.1%) and a lower incidence of MACNBE (45.5% vs 55.2%).
- **Adjusted results**: After inverse probability weighting, anti - platelet therapy was significantly associated with lower 1 - year mortality (adjusted hazard ratio [HR] 0.64, 95% CI 0.62 - 0.66, P < 0.001) and MACNBE (adjusted HR 0.69, 95% CI 0.67 - 0.71, P < 0.001).

### Discussion
The research results show that in atrial fibrillation patients not prescribed OAC, the use of anti - platelet therapy at discharge is associated with lower 1 - year mortality and MACNBE risk. This finding supports the current guidelines' recommendation on using aspirin for secondary prevention before starting or restarting OAC. Although the effectiveness of anti - platelet therapy in preventing non - cardioembolic stroke or transient ischemic attack (TIA) has been widely recognized, its application in atrial fibrillation patients still needs further research.